MedPath
HSA Approval

AVAMAB Concentrate for Solution for Infusion 100mg/4mL

SIN17101P

AVAMAB Concentrate for Solution for Infusion 100mg/4mL

AVAMAB Concentrate for Solution for Infusion 100mg/4mL

September 25, 2024

INNOGENE KALBIOTECH PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantINNOGENE KALBIOTECH PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

L01FG01

Manufacturer Information

INNOGENE KALBIOTECH PTE. LTD.

UNIVERSAL FARMA, S.L.

Active Ingredients

Bevacizumab

100mg/4ml

Bevacizumab

Documents

Package Inserts

Avamab Infusion PI.pdf

Approved: September 25, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.